Appointment

From: Witt, Mike (M) [MEWitt@dow.com]

Sent: 7/20/2017 6:44:33 PM

To: Beck, Nancy [Beck.Nancy@epa.gov]

Subject: Accepted: Meeting w/ Dennis Deziel and Mike Witt from (DOW Chemical Company)

Location: DCRoomEast3156/DC-EPA-EAST-OCSPP

Start: 8/1/2017 7:30:00 PM **End**: 8/1/2017 8:00:00 PM

Show Time As: Busy

Recurrence: (none)

From: Kime, Robin

Location: 3530 WJC North

Importance: Normal

Subject: Meeting with the Color Pigments Manufacturers Association

Start Date/Time: Wed 6/7/2017 5:00:00 PM Wed 6/7/2017 5:30:00 PM

CPMA 2015 Annual Report.pdf CPMA 2016 Annual Report.pdf

Directions: Please use the William Jefferson Clinton North Entrance located on your right as you exit the Federal Triangle Metro Station. Please arrive 20 minutes prior to the meeting with photo IDs to clear Security.

EPA Contact: For an escort from Security to the meeting call Ex. 6 - Personal Privacy other matters call Ex. 6 - Personal Privacy

Attendees:

John Marten, President, Shepherd Color Company

Eric Christman, Vice President, Pigment Manufacturing NA, BASF Colors & Effects

Steve Camenisch, Product Stewardship, BASF Colors & Effects

Brooke DiDomenico, Technical Manager, Nation Ford Chemical

William Fetterly, Global Product Stewardship, BASF Colors & Effects

Frank Gillette, Site Manager, Flint Group Pigments

Dave Klebine, President, Apollo Colors

Ron Levi, President, Bruchsaler

Brian Marsicano, Managing Director, BASF Colors & Effects

Robert Mott, Global Regulatory Manger, Sun Chemical Corporation

Myron Petruch, President, Sun Chemical Corporation

Aram Terzian, Head of Dealer Management, EMD Performance Materials

Luiz Vieira, President, EMD Performance Materials

David Wawer, CPMA Executive Director

Glenn Merritt, CPMA Issues Counsel, Fitzpatrick & Merritt

Jamie Conrad, CPMA Agency Counsel, Conrad Law

Robert Helminiak, Managing Director, SOCMA Government Relations

Request: We understand that it would be most convenient to meet at the EPA HQ and are prepared to bring a group of our Board Members for a meeting. As confirmed by other industry colleagues, we believe that the most appropriate person to meet with would be Brittany, as she is an executive level political appointee that represents the policies of the new administration. The nature of the discussion is not meant to be technical, but rather focus on policies moving forward under the new EPA administrator. The discussion may also address EPA-related regulatory challenges:

- 1. The U.S. color pigment manufacturing industry, its downstream customers and its domestic economic impacts
- 2. Principal EPA-related regulatory challenges:
- a. TSCA risk evaluations of Work Plan pigments, starting with Violet 29
- b. Proper role of EPA regions in setting state water quality criteria Region 10 override of WA DoE

Contact:

Tatiana Letcheva, Manager

Color Pigments Manufacturers Association, Inc. 1400 Crystal Drive, Suite 630

Arlington, VA 22202 (571) 348-5124

www.pigments.org

From: Deziel, Dennis (DR)

DCRoomEast3156/DC-EPA-EAST-OCSPP Location:

Importance: Normal

Subject: Accepted: Meeting w/ Dennis Deziel & Mike Witt (DOW Chemical Company)--alternative Testing

Start Date/Time: Tue 8/1/2017 7:30:00 PM End Date/Time: Tue 8/1/2017 8:00:00 PM

Appointment

From: Cleland-Hamnett, Wendy [Cleland-Hamnett.Wendy@epa.gov]

Sent: 7/25/2017 1:27:49 AM

To: Beck, Nancy [Beck.Nancy@epa.gov]

Subject: Tentative: Meeting w/ Dennis Deziel and Mike Witt from (DOW Chemical Company)

Location: DCRoomEast3156/DC-EPA-EAST-OCSPP

Start: 8/1/2017 7:30:00 PM **End**: 8/1/2017 8:00:00 PM

Recurrence: (none)

Nancy, what's the topic of this one?

To: Beck, Nancy[Beck.Nancy@epa.gov]
From: HOPPER, SARA ELIZABETH
Sent: Thur 6/22/2017 8:45:03 PM
Subject: meeting re: TSCA Section 5

Hi Nancy. Just left you a voice mail. Would you have time to meet with my colleague, Lynn Dekleva, and me to discuss our recent experiences with the new chemicals program? Lynn will be in town next week and we would have some time Wed. afternoon the 28th. If that doesn't work on your end, could we look at the week of July 10th, or the following week if needed?

Sara

Sara Hopper

Manager, Federal Government Affairs

DuPont Government Affairs

601 Pennsylvania Avenue NW

Suite 325, North Building

Ex. 6 - Personal Privacy

Washington, DC 20004

This communication is for use by the intended recipient and contains information that may be Privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail,in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e-mail does not constitute a contract offer, a contract amendment, or an

acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's
contact information for direct marketing purposes or for transfers of data to third parties.

Français Deutsch Italiano Espanol Portugues Japanese Chinese Korean


Ex. 6 - Personal Privacy

From: Sent: Subject:	James McVaney Wed 7/19/2017 5:34:26 PM Row crop farm tour - Corn
Mathews Coalition	nen we first spoke you mentioned that you would like to tour a row crop farm. I have cc'd Ethan of the National Corn Growers Association. You will be with him tomorrow at the Pesticide Policy meeting, which he co-chairs. NCGA would be able to organize a tour for you and other Agency would be informative and show the use of FIFRA regulated products in that setting.
I'll leave it	to Ethan to follow up but wanted to "set the table."
Best,	
Jim	
Jim McV	aney
Senior D	irector, Federal Affairs & Policy
Bayer: Sc	ience For A Better Life
Bayer Corpo	pration
Bayer Corp-	CGR-USGR
801 Pennsyl	vania Avenue, NW
Suite 745	
Washington,	DC 20004 US

To:

Cc:

Beck, Nancy[Beck.Nancy@epa.gov] Ethan Mathews[mathews@dc.ncga.com]



The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.

From: Microsoft Outlook

Location: DCRoomEast3156/DC-EPA-EAST-OCSPP

Importance: Normal

Subject: Meeting Forward Notification: Meeting w/ Dennis Deziel & Mike Witt (DOW Chemical

Company)--alternative Testing

Start Date/Time: Tue 8/1/2017 7:30:00 PM **End Date/Time:** Tue 8/1/2017 8:00:00 PM

Your meeting was forwarded

<u>Pierce, Alison</u> has forwarded your meeting request to additional recipients.

Meeting

Meeting w/ Dennis Deziel & Mike Witt (DOW Chemical Company)--alternative Testing

Meeting Time

Tuesday, August 1, 2017 3:30 PM-4:00 PM.

Recipients

Scarano, Louis

All times listed are in the following time zone: (UTC-05:00) Eastern Time (US & Canada)

Sent by Microsoft Exchange Server

To: Beck, Nancy[Beck.Nancy@epa.gov]

Cc: Marshall, Venus[Marshall.Venus@epa.gov]; DEKLEVA, LYNN ANN[Lynn-Ann.Dekleva-

1@dupont.com]

From: HOPPER, SARA ELIZABETH
Sent: Fri 6/23/2017 8:22:13 PM
Subject: RE: meeting re: TSCA Section 5

Thanks very much Nancy and Venus! We have a time on your calendar on July 10th. Venus, I forwarded the invite to my colleague Lynn Dekleva, copied above, so you should get a response from her too. Nancy, Lynn and I thought it might make sense for Jeff Morris to join us, if you agree. Re: specific topics, Lynn should probably weigh in, but at a high level, the need for transparency and more open communication is one area of concern for us, and a tendency towards overly precautionary approaches and actions (vs. the risk-based approach mandated by LCSA) is another. I hope that is helpful. If more background would be helpful, I can work with Lynn to get that to you.

Thanks again to both you and Venus for responding so quickly and helping us to get this set up.

Have a great weekend!

Sara

From: Beck, Nancy [mailto:Beck.Nancy@epa.gov]

Sent: Thursday, June 22, 2017 6:21 PM

To: HOPPER, SARA ELIZABETH < Sara. E. Hopper@dupont.com>

Cc: Marshall, Venus < Marshall. Venus@epa.gov>

Subject: [EXTERNAL] RE: meeting re: TSCA Section 5

Hi Sarah,

Next week is pretty crazy but I think we can find 30 min the week of July 10. Venus, can you please help us find a window?

If there is a specific topic within the new chemicals program and you would like some of our

leadership team to join me please let me know.
Regards, Nancy
Nancy B. Beck, Ph.D., DABT
Deputy Assistant Administrator, OCSPP
Ex. 6 - Personal Privacy
beck.nancy@epa.gov
From: HOPPER, SARA ELIZABETH [mailto:Sara.E.Hopper@dupont.com] Sent: Thursday, June 22, 2017 4:45 PM To: Beck, Nancy < Beck.Nancy@epa.gov > Subject: meeting re: TSCA Section 5
Hi Nancy. Just left you a voice mail. Would you have time to meet with my colleague, Lynn Dekleva, and me to discuss our recent experiences with the new chemicals program? Lynn will be in town next week and we would have some time Wed. afternoon the 28 th . If that doesn't work on your end, could we look at the week of July 10 th , or the following week if needed?
Thank you very much!
Sara
Sara Hopper

Manager, Federal Government Affairs

DuPont Government Affairs

601 Pennsylvania Avenue NW

Suite 325, North Building

Washington, DC 20004

Ex. 6 - Personal Privacy

sara.e.hopper@dupont.com

This communication is for use by the intended recipient and contains information that may be Privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail, in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e-mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for transfers of data to third parties.

Français Deutsch Italiano Espanol Portugues Japanese Chinese Korean

http://www.DuPont.com/corp/email_disclaimer.html

This communication is for use by the intended recipient and contains information that may be Privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail,in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e-mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for transfers of data to third parties.

Français Deutsch Italiano Espanol Portugues Japanese Chinese Korean

 $http://www.DuPont.com/corp/email_disclaimer.html$

To: From: Sent: Subject:	Beck, Nancy[Beck.Nancy@epa.gov] James McVaney Fri 6/23/2017 6:03:19 PM ACC Alum and Meeting follow up
Nancy,	
issues. I h	ollow up on a meeting you had last week with a group from CropLife, and to connect on specific ave sent an LinkedIn request to connect, noting that I am also an ACC Alum, having run the d climate team in the early 2000s. I currently run all of Bayer's advocacy for our CropScience
group from	g we can get coffee next week to talk shop and follow up on the meeting you had with the a CropLife last week. We were not able to be present but have a number of things cooking right se let me know if you have availability.
Best,	
Jim	
Jim McV	aney
Senior Di	rector, Federal Affairs & Policy
Bayer: Sci	ence For A Better Life
Bayer Corpo	ration
Bayer Corp-0	CGR-USGR

801 Pennsylvania Avenue, NW

Suite 745

Washington, DC 20004 US

Ex. 6 - Personal Privacy

E-mail: james.mcvaney@bayer.com

Web: http://www.bayer.com

-

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.

To: Cc: From: Sent:	Beck, Nancy[Beck.Nancy@epa.gov]; Marshall, Venus[Marshall.Venus@epa.gov] Witt, Mike (M)[MEWitt@dow.com] Deziel, Dennis (DR) Wed 7/19/2017 2:01:48 PM		
Subject:	RE: Chemical Makers Urge EPA to Accept Non-Animal Safety Data		
Venus,			
	e available on August 1 at either 11am or anytime 3:30pm or later. 30 minutes would Thank you!		
From: Beck, Nancy [mailto:Beck.Nancy@epa.gov] Sent: Tuesday, July 18, 2017 5:44 PM To: Deziel, Dennis (DR) <drdeziel@dow.com> Cc: Marshall, Venus <marshall.venus@epa.gov> Subject: RE: Chemical Makers Urge EPA to Accept Non-Animal Safety Data</marshall.venus@epa.gov></drdeziel@dow.com>			
Dennis—			
I'm happy to meet with Mike Witt and can invite our leads for the development of our alternatives strategy.			
Please wo	ork with Venus to find a 30 minute window that will work.		
Nancy			
Nancy B.	Beck, Ph.D., DABT		
Deputy A	Assistant Administrator, OCSPP		
Ex. 6 - Pers	onal Privacy		

beck.nancy@epa.gov

From: Deziel, Dennis (DR) [mailto:DRDeziel@dow.com]

Sent: Tuesday, July 18, 2017 1:18 PM **To:** Beck, Nancy < <u>Beck.Nancy@epa.gov</u>>

Subject: Chemical Makers Urge EPA to Accept Non-Animal Safety Data

Nancy,

Dow is a leader in non-animal testing methods, including extensive, collaborative work with EPA's National Center for Computational Toxicology. We want to engage on this issue in as helpful way as possible. One of our leaders on this issue, Mike Witt, head of our toxicology center, will be in town August 1st. Would you be available to meet when he is here to discuss this issue? Or we could meet with others as you recommend.

Thank you, Dennis

Dennis Deziel Government Affairs

The Dow Chemical Company

500 North Capitol Street, NW Suite 200

Washington DC 20001
Ex. 6 - Personal Privacy

E-Mail: DRDeziel@dow.com



Bloomberg News

Chemical Makers Urge EPA to Accept Non-Animal Safety Data

By Pat Rizzuto

Chemical manufacturers want the EPA to be more receptive than they say the European Chemicals Agency has been in accepting chemical safety data derived from non-animal tests.

"We've had challenges in the EU getting many of these alternatives accepted. We hope the U.S. will be a more friendly place," Athena Keene, a senior toxicologist at Afton Chemical Corp., said at a recent science policy meeting.

Afton, a subsidiary of the NewMarket Corp., which makes fuel and lubricant additives, has registered chemicals under the EU's registration, evaluation, authorization and restriction of chemicals, or REACH, law. REACH encourages the use of non-animal tests, yet animal welfare groups and chemical manufacturers have appealed many decisions in which the European Chemicals Agency rejected non-animal data the companies sought to submit.

The Environmental Protection Agency soon will invite chemical manufacturers, trade associations, animal welfare advocates, and academic and other scientists to help shape an agency strategy to develop and use the results from non-animal, or "alternative," tests for chemical decision making, said Tala Henry, who directs the risk assessment division of the EPA's Office of Pollution Prevention and Toxics. Keene and Henry were among the speakers at a July 12 Toxicology Forum meeting that discussed the Lautenberg Chemical Safety Act, which amended the Toxic Substances Control Act in 2016.

TSCA's amendments require the EPA to develop a non-animal testing strategy by June 22, 2018, to promote the development and use of new scientifically valid test methods that don't use mammals or other vertebrates. That strategy is part a broader requirement for EPA to reduce and replace the use of animals at a time when more tests may be required.

The EPA is deciding whether to seek public participation through a workshop, releasing a draft concept document, or some other method, Henry said. The agency expects to invite interested parties to provide input in a few months, she said.

Reducing Liability

Harvey Clewell, a senior scientist at ScitoVation, a research institute specializing in cell-based and computational methods as chemical evaluation methods, echoed Keene's point that some European chemical regulators have not used available non-animal test methods.

The U.S., however, has a growing academic, federal and industry scientific infrastructure supporting their development and use, he said. Clewell pointed to federal agencies such the EPA and National Institute of Environmental Health Sciences (NIEHS), which have been developing and using a spectrum of automated chemical testing systems.

Using alternative tests "just makes good sense," especially in the early stages of a new chemical's development, Clewell said. "There's a lot of liability potential for chemicals. They can cost a company a lot of money once they are out there. Wouldn't it behoove a company to run some quick tests and say 'this has red flags why should we pursue it'."

Suzanne Hartigan, director of science policy and regulatory affairs at the International Fragrance Association North America, said fragrance makers already have developed strategies to obtain chemical safety data from alternative tests, so they could comply with the EU's Cosmetics Products Regulation and its predecessor—the Cosmetics Directive—which phased out the use of animal tests on cosmetics and their ingredients.

The Research Institute for Fragrance Materials, Inc., which assesses fragrance safety, has developed a phased in, or "tiered," testing strategy that begins with evaluating existing data for a particular fragrance, proceeds to examining information about similar compounds, and builds toward in vitro and computer-modeled tests, Hartigan said. After such alternative data sources have been utilized, animal tests can be considered, she said, urging EPA to consider some of these strategies.

No Double Standard

Henry said EPA already would review non-animal chemical safety data if companies submitted it but added, "It's not flooding into us."

The more companies submit alternative data, the more it will help the agency understand their uses and limitations, she said.

Richard Denison, lead senior scientist with the Environmental Defense Fund, said that group supports the use of alternative tests. Details about tests used to generate data submitted to the EPA should, however, be made available to build public confidence in the tests' predictions, he said. Protocols used for statutorily required animal tests are publicly available.

Many of the assays the EPA uses for its automated chemical testing program, called ToxCast, and that the NIEHS uses for a similar program called Tox21, are proprietary, Denison said.

Alternative test advocates also should avoid a double standard, Denison said.

There's a tendency for proponents to want to use data from an alternative test if it suggests a chemical would not raise health or environmental concerns, he said. Yet if such tests show a problem, then the proponents argue the tests aren't valid because they don't reflect the "real world," Denison said.

To: Beck, Nancy[Beck.Nancy@epa.gov]

Cc: Marshall, Venus[Marshall.Venus@epa.gov]

From: Sent: James McVaney

Thur 7/6/2017 3:05:50 PM

Subject: Re: ACC Alum and Meeting follow up

Dr Beck,

I am a bit early and at the reception desk.

Thanks,

Jim

Jim McVaney

Senior Director, Federal Affairs & Policy

Bayer: Science For A Better Life

Bayer Corporation

Bayer Corp-CGR-USGR

801 Pennsylvania Avenue, NW

<u>Suite 745</u>

Washington, DC 20004 US

Ex. 6 - Personal Privacy

E-mail: james.mcvaney@bayer.com

Web: http://www.bayer.com

Hi Jim,
Nice to "meet" you. My calendar is pretty crazy packed next week. Why don't we try for a 30 minute window after the July 4 th holiday.
Venus, can you help us find a window?
Regards,
Nancy
Nancy B. Beck, Ph.D., DABT
Deputy Assistant Administrator, OCSPP
Ex. 6 - Personal Privacy
beck.nancy@epa.gov
From: James McVaney [mailto:james.mcvaney@bayer.com] Sent: Friday, June 23, 2017 2:03 PM To: Beck, Nancy < Beck.Nancy@epa.gov > Subject: ACC Alum and Meeting follow up
Nancy,

This is to follow up on a meeting you had last week with a group from CropLife, and to connect on specific issues. I have sent an LinkedIn request to connect, noting that I am also an ACC Alum, having run the energy and climate team in the early 2000s. I currently run all of Bayer's advocacy for

On Jun 23, 2017, at 5:54 PM, Beck, Nancy < Beck.Nancy@epa.gov > wrote:

our CropScience business. I am hoping we can get coffee next week to talk shop and follow up on the meeting you had with the group from CropLife last week. We were not able to be present but have a number of things cooking right now. Please let me know if you have availability. Best, Jim Jim McVaney Senior Director, Federal Affairs & Policy Bayer: Science For A Better Life **Bayer Corporation** Bayer Corp-CGR-USGR 801 Pennsylvania Avenue, NW Suite 745 Washington, DC 20004 US Ex. 6 - Personal Privacy

E-mail: james.mcvaney@bayer.com

Web: http://www.bayer.com

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.

To: Beck, Nancy[Beck.Nancy@epa.gov]

From: Deziel, Dennis (DR) **Sent:** Tue 7/18/2017 5:18:18 PM

Subject: Chemical Makers Urge EPA to Accept Non-Animal Safety Data

Nancy,

Dow is a leader in non-animal testing methods, including extensive, collaborative work with EPA's National Center for Computational Toxicology. We want to engage on this issue in as helpful way as possible. One of our leaders on this issue, Mike Witt, head of our toxicology center, will be in town August 1st. Would you be available to meet when he is here to discuss this issue? Or we could meet with others as you recommend.

Thank you, Dennis

Dennis Deziel Government Affairs

The Dow Chemical Company

500 North Capitol Street, NW Suite 200

Washington DC 20001

Ex. 6 - Personal Privacy

E-Mail: DRDeziel@dow.com



--

Bloomberg News

Chemical Makers Urge EPA to Accept Non-Animal Safety Data

By <u>Pat Rizzuto</u>

Chemical manufacturers want the EPA to be more receptive than they say the European Chemicals Agency has been in accepting chemical safety data derived from non-animal tests.

"We've had challenges in the EU getting many of these alternatives accepted. We hope the U.S. will be a more friendly place," Athena Keene, a senior toxicologist at Afton Chemical Corp., said at a recent science policy meeting.

Afton, a subsidiary of the NewMarket Corp., which makes fuel and lubricant additives, has registered chemicals under the EU's registration, evaluation, authorization and restriction of chemicals, or REACH, law. REACH encourages the use of non-animal tests, yet animal welfare groups and chemical manufacturers have appealed many decisions in which the European Chemicals Agency rejected non-animal data the companies sought to submit.

The Environmental Protection Agency soon will invite chemical manufacturers, trade associations, animal welfare advocates, and academic and other scientists to help shape an agency strategy to develop and use the results from non-animal, or "alternative," tests for chemical decision making, said Tala Henry, who directs the risk assessment division of the EPA's Office of Pollution Prevention and Toxics. Keene and Henry were among the speakers at a July 12 Toxicology Forum meeting that discussed the Lautenberg Chemical Safety Act, which amended the Toxic Substances Control Act in 2016.

TSCA's amendments require the EPA to develop a non-animal testing strategy by June 22, 2018, to promote the development and use of new scientifically valid test methods that don't use mammals or other vertebrates. That strategy is part a broader requirement for EPA to reduce and replace the use of animals at a time when more tests may be required.

The EPA is deciding whether to seek public participation through a workshop, releasing a draft concept document, or some other method, Henry said. The agency expects to invite interested parties to provide input in a few months, she said.

Reducing Liability

Harvey Clewell, a senior scientist at ScitoVation, a research institute specializing in cell-based and computational methods as chemical evaluation methods, echoed Keene's point that some European chemical regulators have not used available non-animal test methods.

The U.S., however, has a growing academic, federal and industry scientific infrastructure supporting their development and use, he said. Clewell pointed to federal agencies such the EPA and National Institute of Environmental Health Sciences (NIEHS), which have been developing and using a spectrum of automated chemical testing systems.

Using alternative tests "just makes good sense," especially in the early stages of a new chemical's development, Clewell said. "There's a lot of liability potential for chemicals. They can cost a company a lot of money once they are out there. Wouldn't it behoove a company to run some quick tests and say 'this has red flags why should we pursue it'."

Suzanne Hartigan, director of science policy and regulatory affairs at the International Fragrance Association North America, said fragrance makers already have developed strategies to obtain chemical safety data from alternative tests, so they could comply with the EU's Cosmetics Products Regulation and its predecessor—the Cosmetics Directive—which phased out the use of animal tests on cosmetics and their ingredients.

The Research Institute for Fragrance Materials, Inc., which assesses fragrance safety, has

developed a phased in, or "tiered," testing strategy that begins with evaluating existing data for a particular fragrance, proceeds to examining information about similar compounds, and builds toward in vitro and computer-modeled tests, Hartigan said. After such alternative data sources have been utilized, animal tests can be considered, she said, urging EPA to consider some of these strategies.

No Double Standard

Henry said EPA already would review non-animal chemical safety data if companies submitted it but added, "It's not flooding into us."

The more companies submit alternative data, the more it will help the agency understand their uses and limitations, she said.

Richard Denison, lead senior scientist with the Environmental Defense Fund, said that group supports the use of alternative tests. Details about tests used to generate data submitted to the EPA should, however, be made available to build public confidence in the tests' predictions, he said. Protocols used for statutorily required animal tests are publicly available.

Many of the assays the EPA uses for its automated chemical testing program, called ToxCast, and that the NIEHS uses for a similar program called Tox21, are proprietary, Denison said.

Alternative test advocates also should avoid a double standard, Denison said.

There's a tendency for proponents to want to use data from an alternative test if it suggests a chemical would not raise health or environmental concerns, he said. Yet if such tests show a problem, then the proponents argue the tests aren't valid because they don't reflect the "real world," Denison said.

To: Beck, Nancy[Beck.Nancy@epa.gov]

From: Goldstein, Bernard D

Sent: Wed 5/31/2017 7:12:06 PM

Subject: RE: Follow-up on SRA Session

Hi Nancy

Most recent version of proposal is below. The five speakers for 10 min each in alphabetical order are Arvai, Beck, Denison, Goldstein and White. I need to get this in by **tonight**

Also – would you like to be listed with a middle initial?

Thanks again for doing this

Bernie

From: Beck, Nancy [mailto:Beck.Nancy@epa.gov]

Sent: Monday, May 22, 2017 6:49 PM

To: Goldstein, Bernard D <bdgold@pitt.edu> **Subject:** RE: Follow-up on SRA Session

Got it. When you have a final abstract send it my way and I'll take a look.

It is a bit awkward.. I think I can be on a panel with them, but do not want to be collaborating with them, or even seen as collaborating with them.

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Monday, May 22, 2017 3:52 PM
To: Beck, Nancy < Beck. Nancy @epa.gov >
Subject: RE: Follow-up on SRA Session

Sorry to be unclear. I do need names for the submission, but do not need your participation in the preparation of the abstract. I apologize, as I should have realized that this might be a problem for you

Needless to say, you could withdraw at any time.

Bernie

From: Beck, Nancy [mailto:Beck.Nancy@epa.gov]

Sent: Monday, May 22, 2017 7:42 AM

To: Goldstein, Bernard D < <u>bdgold@pitt.edu</u>> **Subject:** RE: Follow-up on SRA Session

Bernie,

As I am recused from interactions with ACC, it's a bit awkward for me to be planning a session with them.

As you said you don't need names just yet for the submission, why don't you just move ahead

without me and lets circle back in the fall to see if it makes sense for me to join the panel.
Regards,
Nancy
Nancy B. Beck, Ph.D., DABT
Deputy Assistant Administrator, OCSPP
Ex. 6 - Personal Privacy

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Monday, May 22, 2017 5:24 AM

To: White, Kimberly < <u>Kimberly White@americanchemistry.com</u>>

Cc: Rick Becker@americanchemistry.com; Joe Arvai < ilarvai@umich.edu >; Beck, Nancy

<Beck.Nancy@epa.gov>

beck.nancy@epa.gov

Subject: RE: Follow-up on SRA Session

Hi Kimberly

Your changes are OK with me, but I have added a few words ("and decreasing the likelihood of the involvement of knowledgeable academic scientists in EPA review processes") to reflect the substantial concern of the academic community about the following provision in the SAB Act. (I also think that the provision is short-sighted from an industry perspective).

"(H) a Board member shall have no current grants or contracts from the Environmental Protection Agency

and shall not apply for a grant or contract for 3 years following the end of that member's service on the Board."

There is also other language in the Act which could be interpreted as the above provision being applicable to not only full SAB Board membership, but to the members of any EPA review process of any hazard or risk assessment

Let me know if the new language is acceptable to you. I'm also copying Joe Arvai and Nancy Beck in case they want to respond, either in writing or by phone, particularly as there is now no description of Administrator Pruitt's goals or activities in this area. While not necessary, we do have room in the abstract for additional language

Bernie

Bernard D. Goldstein, MD

Professor Emeritus and Dean Emeritus

University of Pittsburgh Graduate School of Public Health

130 Desoto St; Rm A-710

Pittsburgh PA 15261

Ex. 6 - Personal Privacy

From: White, Kimberly [mailto:Kimberly White@americanchemistry.com]

Sent: Friday, May 19, 2017 6:22 PM

To: Goldstein, Bernard D < bdgold@pitt.edu>
Cc: Becker, Rick < Rick Becker@americanchemistry.com>
Subject: RE: Follow-up on SRA Session

Dear Bernie:

Thanks for the additional information about the session and the abstract. We offer some suggestions to the abstract attached. The suggestions attempt to focus the abstract on the discussion regarding what are appropriate approaches for optimal provision of scientific advice to regulatory agencies and work to adjust some of the language that may be perceived as inflammatory.

Kind Regards,

Kimberly

Kimberly Wise White, Ph.D. | American Chemistry Council

Senior Director, Chemical Products & Technology Division

Kimberly White@americanchemistry.com

700 2nd Street NE | Washington, DC | 20002

Ex. 6 - Personal Privacy

www.americanchemistry.com

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Friday, May 19, 2017 2:53 PM

To: White, Kimberly

Cc: Becker, Rick Subject: RE: Follow-up on SRA Session
Dear Dr White
Great news!!
My previous email to you is below; along with the original attachment of the preliminary draft
Bernie
Bernard D. Goldstein, MD
Emeritus Professor and Emeritus Dean
Graduate School of Public Health
University of Pittsburgh
Rm A710 Crabtree Hall
130 De Soto St
Pittsburgh, PA 15261
Ex. 6 - Personal Privacy
Dear Dr White
I am following up with you at the suggestion of Nancy Beck (email below) to request your

involvement in a proposal for a Roundtable to be submitted to the Society for Risk Analysis for its annual meeting in Crystal City next December 10-13.

I've attached a short overview of Roundtables from the SRA web site along with a rough draft of the abstract. I am trying to focus the Roundtable on the parameters governing an effective science advisory process for a regulatory agency, rather than on the current controversy – although this is unlikely to be fully possible.

NOTE: no abstract would be needed from you, just an agreement to participate, give perhaps a 10 minute presentation and participate in the discussion during the 90 minute session. But your input on the proposal would be welcome.

One difference from the note below to Nancy is that I have been told that the proposal is more likely to be acceptable if it has a broader range of participants so it will probably 4-5 speakers rather than 3-4.

I had previously reached out to Richard Becker asking for whom to approach at ACC now that Nancy had left. His response was that ACC would be interested in participating but only if EPA did as well, which I fully understand. I know he is out of town today. As you no doubt know, ACC is on record supporting the EPA SAB Act that passed the House.

There are some time constraints in getting this completed, particularly as I will be at Dow Chemical for much of next week, so hope both that you can do this and that you can respond by midweek

Many thanks for your consideration

Bernie

Bernard D. Goldstein, MD

Emeritus Professor and Emeritus Dean

Graduate School of Public Health

University of Pittsburgh

Rm A710 Crabtree Hall

130 De Soto St

Pittsburgh, PA 15261

Ex. 6 - Personal Privacy

From: Goldstein, Bernard D

Sent: Thursday, May 18, 2017 2:28 PM **To:** Beck, Nancy <Beck.Nancy@epa.gov>

Subject: Re: SRA panel

Happy to reframe. I originally had a quote from the congressman who sponsored it but this seemed too inflammatory for SRA. Will look at this again tonight and will contact Kimberly White

Sent from my iPhone

On May 18, 2017, at 12:08 PM, Beck, Nancy < Beck. Nancy@epa.gov > wrote:

Bernie,

I think the framing of the abstract is a bit biased and needs some work.

I cant and wont speak for ACC at all, but for this topic, I direct you to Kimberly White. She has testified in front of congress on these issues. <u>Kimberly White@americanchemistry.com</u>.

If I have more time this week I will noodle the abstract but it's a bit of a busy time here.		
Regards, Nancy		
Nancy B. Beck, Ph.D., DABT		
Deputy Assistant Administrator, OCSPP		
Ex. 6 - Personal Privacy		
beck.nancy@epa.gov		
From: Goldstein, Bernard D [mailto:bdgold@pitt.edu] Sent: Wednesday, May 17, 2017 12:41 PM To: Beck, Nancy < Beck.Nancy@epa.gov > Subject: RE: SRA panel		
Hi Nancy		
Great to hear!!		
Attached is what I've written so far, and some of the directions from the SRA web site. I'm about to run out for most of the rest of the afternoon. I'd like to get this out of the way as soon as reasonably possible as am at meetings at Dow most of next week.		

No abstract would be needed from you so there is nothing written with your name on it that would have to go through the EPA process, at least as I understood it many, many years ago. (As the proposer, I would be the only one with my name on the proposed abstract, but would welcome your input and that of the other panelists on the proposal).

I'm envisioning the 3 or 4 panelists for the Roundtable would have about 15 min each for presentation and the rest of the 90 minutes would be for a facilitated discussion led by the moderator

I'm thinking of asking Granger Morgan or Terry Yosie to be the moderator, but your suggestion for moderator or for another panelist who supports the ACC position on the SAB Act would be very much appreciated.

Best regards

Bernie

Bernard D. Goldstein, MD

Emeritus Professor and Emeritus Dean

Graduate School of Public Health

University of Pittsburgh

Rm A710 Crabtree Hall

130 De Soto St

Pittsburgh, PA 15261

Ex. 6 - Personal Privacy

From: Beck, Nancy [mailto:Beck.Nancy@epa.gov]

Sent: Wednesday, May 17, 2017 12:22 PM

To: Goldstein, Bernard D < bdgold@pitt.edu >

Subject: SRA panel

Hi Bernie,

Got your message and am happy to consider the request. Can you send me all the information on the proposal (abstract, goals, participants, etc)?

I will have to find out if I have to run this through a clearance process—not sure how that works yet and if those procedures apply to me.

Thanks, Nancy

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator

Office of Chemical Safety and Pollution Prevention

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: White, Kimberly [mailto:Kimberly White@americanchemistry.com]

Sent: Friday, May 19, 2017 2:35 PM

To: Goldstein, Bernard D < bdgold@pitt.edu >

Cc: Becker, Rick < Rick Becker@americanchemistry.com>

Subject: Follow-up on SRA Session

Dear Dr. Goldstein:

Thank you for your voicemail earlier today. I have had an opportunity to follow-up with Rick (cc'd on this email) and I understand you have a commitment from EPA to participate. Given the confirmation of EPA's participation, we will also confirm ACC's participation. Could you send me the proposed abstract or session description? Also it would be helpful to know of any additional information you need from ACC for the session and any deadlines.

Kind Regards,

Kimberly Wise White, Ph.D. | American Chemistry Council

Senior Director, Chemical Products & Technology Division

Kimberly White@americanchemistry.com

700 2nd Street NE | Washington, DC | 20002

Ex. 6 - Personal Privacy

www.americanchemistry.com

 as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this message which arise as a result of email transmission. American Chemistry Council, 700 – 2nd Street NE, Washington, DC 20002, www.americanchemistry.com

To: Cleland-Hamnett, Wendy[Cleland-Hamnett.Wendy@epa.gov]

Cc: Beck, Nancy[Beck.Nancy@epa.gov]; Jakob, Avivah[Jakob.Avivah@epa.gov]

From: Dunton, Cheryl

Sent: Wed 6/14/2017 8:57:45 PM

Subject: RE: Press Inquiry from Bloomberg on Glyphosate

Great thanks. Will send to OPA.

From: Cleland-Hamnett, Wendy

Sent: Wednesday, June 14, 2017 4:57 PM **To:** Dunton, Cheryl < Dunton. Cheryl@epa.gov>

Cc: Beck, Nancy <Beck.Nancy@epa.gov>; Jakob, Avivah <Jakob.Avivah@epa.gov>

Subject: Re: Press Inquiry from Bloomberg on Glyphosate

Ok with me

Wendy Cleland-Hamnett

Acting Assistant Administrator

Principal Deputy Assistant Administrator

Office of Chemical Safety & Pollution Prevention

U.S. EPA

On Jun 14, 2017, at 3:32 PM, Dunton, Cheryl < <u>Dunton.Cheryl@epa.gov</u>> wrote:

See incoming below from Bloomberg on glyphosate and our response in red.

Ex. 5 - Deliberative Process

Ex. 5 - Deliberative Process Let me know if you have comments/edits before this goes to OPA.

Incoming:

From Michael Byhoff, Producer - Bloomberg

Ex. 6 - Personal Privacy

I am a producer for Bloomberg news and I'm working on a video about Monsanto, and more specifically, the impact of glyphosate on farming.
It is a video from the objective viewpoint of "what would the world look like if we stopped using glyphosate" The piece is about how glyphosate has changed the world of farming, and what life would be like if it was found out to be carcinogenic.
For example, how would a farmer's life change, what would happen to produce prices in the grocery store, and what the alternatives (if any) is in place to replace glyphosate.
I want to get the EPA's point of view from the studies brought forth by the IARC that glyphosate could "potentially" be carcinogenic, and see where the government stands from the scientific studies that appear to make the argument on both sides of the argument
Response:
Ex. 5 - Deliberative Process

Ex. 5 - Deliberative Process

Begin forwarded message:

From: "Michael Byhoff (BLOOMBERG/ NEWSROOM:)"

<mbyhoff@bloomberg.net>

Date: May 19, 2017 at 2:02:51 PM EDT

To: <<u>Jones.Enesta@epa.gov</u>>
Subject: Re:EPA Inquiry

Reply-To: Michael Byhoff mbyhoff@bloomberg.net>

The piece is about how glyphosate has changed the world of farming, and what life would be like if it was found out to be carcinogenic.

For example, how would a farmer's life change, what would happen to produce prices in the grocery store, and what the alternatives (if any) is in place to replace glyphosate.

I want to get the EPA's point of view from the studies brought forth by the IARC that glyphosate could "potentially" be carcinogenic, and see where the government stands from the scientific studies that appear to make the argument on both sides of the argument.

My deadline is early June.

Thanks,

Michael Byhoff

Producer - Bloomberg

Ex. 6 - Personal Privacy

From: Jones.Enesta@epa.gov

Subject: Re:EPA Inquiry

Hi Michael,

I am reaching out RE: your request below. Can you tell me more about your piece, what exactly you are seeking from EPA and your deadline, please?

From: Michael Byhoff (BLOOMBERG/ NEWSROOM:)

[mailto:mbyhoff@bloomberg.net]

Sent: Thursday, May 18, 2017 5:01 PM **To:** Mears, Mary < <u>Mears.Mary@epa.gov</u>>

Subject: Bloomberg news requesting an interview about Glyphosate

Hi Mary,

I am a producer for Bloomberg news and I'm working on a video about Monsanto, and more specifically, the impact of glyphosate on farming.

It is a video from the objective viewpoint of "what would the world look like if we stopped using glyphosate" and was hoping to interview an expert in the area.

I can give you a call to further discuss as well. Let me know if you're available!

Best,

Michael Byhoff

Producer - Bloomberg

Ex. 6 - Personal Privacy

Enesta Jones

U.S. EPA

Office of Media Relations

Ex. 6 - Personal Privacy

"The root of all joy is gratefulness."

To: Goldstein, Bernard D[bdgold@pitt.edu]

From: Beck, Nancy

Sent: Wed 5/31/2017 8:47:59 PM **Subject:** RE: Follow-up on SRA Session

Bernie,

I'm not seeing the proposal.

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Wednesday, May 31, 2017 3:12 PM To: Beck, Nancy <Beck.Nancy@epa.gov> Subject: RE: Follow-up on SRA Session

Hi Nancy

Most recent version of proposal is below. The five speakers for 10 min each in alphabetical order are Arvai, Beck, Denison, Goldstein and White. I need to get this in by **tonight**

Also – would you like to be listed with a middle initial?

Thanks again for doing this Bernie From: Beck, Nancy [mailto:Beck.Nancy@epa.gov] Sent: Monday, May 22, 2017 6:49 PM To: Goldstein, Bernard D < bdgold@pitt.edu > Subject: RE: Follow-up on SRA Session Got it. When you have a final abstract send it my way and I'll take a look. It is a bit awkward.. I think I can be on a panel with them, but do not want to be collaborating with them, or even seen as collaborating with them. Nancy B. Beck, Ph.D., DABT Deputy Assistant Administrator, OCSPP Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Monday, May 22, 2017 3:52 PM
To: Beck, Nancy < Beck. Nancy @epa.gov >
Subject: RE: Follow-up on SRA Session

Fx 6 - Personal Privacy
Deputy Assistant Administrator, OCSPP
Nancy B. Beck, Ph.D., DABT
Trailey
Nancy
Regards,
As you said you don't need names just yet for the submission, why don't you just move ahead without me and lets circle back in the fall to see if it makes sense for me to join the panel.
As I am recused from interactions with ACC, it's a bit awkward for me to be planning a session with them.
Bernie,
From: Beck, Nancy [mailto:Beck.Nancy@epa.gov] Sent: Monday, May 22, 2017 7:42 AM To: Goldstein, Bernard D < bdgold@pitt.edu> Subject: RE: Follow-up on SRA Session
Bernie
Needless to say, you could withdraw at any time.
Sorry to be unclear. I do need names for the submission, but do not need your participation in the preparation of the abstract. I apologize, as I should have realized that this might be a problem for you

Personal Matters / Ex. 6

beck.nancy@epa.gov

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Monday, May 22, 2017 5:24 AM

To: White, Kimberly < Kimberly White@americanchemistry.com >

Cc: Rick Becker@americanchemistry.com; Joe Arvai <i larvai@umich.edu >; Beck, Nancy

< Beck. Nancy@epa.gov>

Subject: RE: Follow-up on SRA Session

Hi Kimberly

Your changes are OK with me, but I have added a few words ("and decreasing the likelihood of the involvement of knowledgeable academic scientists in EPA review processes") to reflect the substantial concern of the academic community about the following provision in the SAB Act. (I also think that the provision is short-sighted from an industry perspective).

"(H) a Board member shall have no current grants or contracts from the Environmental Protection Agency

and shall not apply for a grant or contract for 3 years following the end of that member's service on the Board."

There is also other language in the Act which could be interpreted as the above provision being applicable to not only full SAB Board membership, but to the members of any EPA review process of any hazard or risk assessment

Let me know if the new language is acceptable to you. I'm also copying Joe Arvai and Nancy Beck in case they want to respond, either in writing or by phone, particularly as there is now no description of Administrator Pruitt's goals or activities in this area. While not necessary, we do have room in the abstract for additional language

Bernie

Bernard D. Goldstein, MD

Professor Emeritus and Dean Emeritus

University of Pittsburgh Graduate School of Public Health

130 Desoto St; Rm A-710

Pittsburgh PA 15261

Ex. 6 - Personal Privacy

From: White, Kimberly [mailto:Kimberly_White@americanchemistry.com]

Sent: Friday, May 19, 2017 6:22 PM

To: Goldstein, Bernard D < bdgold@pitt.edu>

Cc: Becker, Rick < Rick Becker@americanchemistry.com>

Subject: RE: Follow-up on SRA Session

Dear Bernie:

Thanks for the additional information about the session and the abstract. We offer some suggestions to

the abstract attached. The suggestions attempt to focus the abstract on the discussion regarding what are appropriate approaches for optimal provision of scientific advice to regulatory agencies and work to adjust some of the language that may be perceived as inflammatory.
Kind Regards,
Kimberly
Kimberly Wise White, Ph.D. American Chemistry Council
Senior Director, Chemical Products & Technology Division
Kimberly White@americanchemistry.com
700 2 nd Street NE Washington, DC 20002
Ex. 6 - Personal Privacy
www.americanchemistry.com
From: Goldstein, Bernard D [mailto:bdgold@pitt.edu] Sent: Friday, May 19, 2017 2:53 PM To: White, Kimberly Cc: Becker, Rick Subject: RE: Follow-up on SRA Session
Dear Dr White
Great news!!
My previous email to you is below; along with the original attachment of the preliminary draft
Bernie

Bernard D. Goldstein, MD

Emeritus Professor and Emeritus Dean

Graduate School of Public Health

University of Pittsburgh

Rm A710 Crabtree Hall

130 De Soto St

Pittsburgh, PA 15261

Ex. 6 - Personal Privacy

Dear Dr White

I am following up with you at the suggestion of Nancy Beck (email below) to request your involvement in a proposal for a Roundtable to be submitted to the Society for Risk Analysis for its annual meeting in Crystal City next December 10-13.

I've attached a short overview of Roundtables from the SRA web site along with a rough draft of the abstract. I am trying to focus the Roundtable on the parameters governing an effective science advisory process for a regulatory agency, rather than on the current controversy – although this is unlikely to be fully possible.

NOTE: no abstract would be needed from you, just an agreement to participate, give perhaps a 10 minute presentation and participate in the discussion during the 90 minute session. But your input on the proposal would be welcome.

One difference from the note below to Nancy is that I have been told that the proposal is more

likely to be acceptable if it has a broader range of participants so it will probably 4-5 speakers rather than 3-4.

I had previously reached out to Richard Becker asking for whom to approach at ACC now that Nancy had left. His response was that ACC would be interested in participating but only if EPA did as well, which I fully understand. I know he is out of town today. As you no doubt know, ACC is on record supporting the EPA SAB Act that passed the House.

There are some time constraints in getting this completed, particularly as I will be at Dow Chemical for much of next week, so hope both that you can do this and that you can respond by midweek

Many thanks for your consideration

Bernie

Bernard D. Goldstein, MD

Emeritus Professor and Emeritus Dean

Graduate School of Public Health

University of Pittsburgh

Rm A710 Crabtree Hall

130 De Soto St

Pittsburgh, PA 15261

Ex. 6 - Personal Privacy

From: Goldstein, Bernard D Sent: Thursday, May 18, 2017 2:28 PM To: Beck, Nancy < Beck. Nancy@epa.gov> Subject: Re: SRA panel Happy to reframe. I originally had a quote from the congressman who sponsored it but this seemed too inflammatory for SRA. Will look at this again tonight and will contact Kimberly White Sent from my iPhone On May 18, 2017, at 12:08 PM, Beck, Nancy < Beck. Nancy@epa.gov > wrote: Bernie, I think the framing of the abstract is a bit biased and needs some work. I cant and wont speak for ACC at all, but for this topic, I direct you to Kimberly White. She has testified in front of congress on these issues. Kimberly White@americanchemistry.com. If I have more time this week I will noodle the abstract but it's a bit of a busy time here. Regards, Nancy Nancy B. Beck, Ph.D., DABT Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Wednesday, May 17, 2017 12:41 PM **To:** Beck, Nancy <<u>Beck.Nancy@epa.gov</u>>

Subject: RE: SRA panel

Hi Nancy

Great to hear!!

Attached is what I've written so far, and some of the directions from the SRA web site. I'm about to run out for most of the rest of the afternoon. I'd like to get this out of the way as soon as reasonably possible as am at meetings at Dow most of next week.

No abstract would be needed from you so there is nothing written with your name on it that would have to go through the EPA process, at least as I understood it many, many years ago. (As the proposer, I would be the only one with my name on the proposed abstract, but would welcome your input and that of the other panelists on the proposal).

I'm envisioning the 3 or 4 panelists for the Roundtable would have about 15 min each for presentation and the rest of the 90 minutes would be for a facilitated discussion led by the moderator

I'm thinking of asking Granger Morgan or Terry Yosie to be the moderator, but your suggestion for moderator or for another panelist who supports the ACC position on the SAB Act would be very much appreciated.

Bernie

Bernard D. Goldstein, MD

Emeritus Professor and Emeritus Dean

Graduate School of Public Health

University of Pittsburgh

Rm A710 Crabtree Hall

130 De Soto St

Pittsburgh, PA 15261

Ex. 6 - Personal Privacy

From: Beck, Nancy [mailto:Beck.Nancy@epa.gov]


Sent: Wednesday, May 17, 2017 12:22 PM
To: Goldstein, Bernard D < bdgold@pitt.edu>

Subject: SRA panel

Hi Bernie,

Got your message and am happy to consider the request. Can you send me all the information on the proposal (abstract, goals, participants, etc)?

I will have to find out if I have to run this through a clearance process—not sure how that works



Dear Dr. Goldstein:

Thank you for your voicemail earlier today. I have had an opportunity to follow-up with Rick (cc'd on this email) and I understand you have a commitment from EPA to participate. Given the confirmation of EPA's participation, we will also confirm ACC's participation. Could you send me the proposed abstract or session description? Also it would be helpful to know of any additional information you need from ACC for the session and any deadlines.

Kind Regards,

Kimberly Wise White, Ph.D. | American Chemistry Council

Senior Director, Chemical Products & Technology Division

Kimberly White@americanchemistry.com

700 2nd Street NE | Washington, DC | 20002

Ex. 6 - Personal Privacy

www.americanchemistry.com

To: HOPPER, SARA ELIZABETH[Sara.E.Hopper@dupont.com]

Cc: Marshall, Venus[Marshall.Venus@epa.gov]

From: Beck, Nancy

Sent: Thur 6/22/2017 10:21:09 PM Subject: RE: meeting re: TSCA Section 5

Hi Sarah,

Next week is pretty crazy but I think we can find 30 min the week of July 10. Venus, can you please help us find a window?

If there is a specific topic within the new chemicals program and you would like some of our leadership team to join me please let me know.

Regards, Nancy

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: HOPPER, SARA ELIZABETH [mailto:Sara.E.Hopper@dupont.com]

Sent: Thursday, June 22, 2017 4:45 PM
To: Beck, Nancy <Beck.Nancy@epa.gov>
Subject: meeting re: TSCA Section 5

Hi Nancy. Just left you a voice mail. Would you have time to meet with my colleague, Lynn Dekleva, and me to discuss our recent experiences with the new chemicals program? Lynn will

be in town next week and we would have some time Wed. afternoon the 28th. If that doesn't work on your end, could we look at the week of July 10th, or the following week if needed?

Thank you very much!

Sara

Sara Hopper

Manager, Federal Government Affairs

DuPont Government Affairs

601 Pennsylvania Avenue NW

Suite 325, North Building

Washington, DC 20004

Ex. 6 - Personal Privacy

sara.e.hopper@dupont.com

This communication is for use by the intended recipient and contains information that may be Privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail, in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e-mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for transfers of data to third parties.

Francais Deutsch Italiano Espanol Portugues Japanese Chinese Korean



To: HOPPER, SARA ELIZABETH[Sara.E.Hopper@dupont.com]

Cc: Marshall, Venus[Marshall.Venus@epa.gov]

From: Beck, Nancy

Sent: Mon 7/24/2017 9:50:54 PM

Subject: RE: meeting to discuss ESA/FIFRA

Hi Sara,

Lets try for 30 minutes the week of the August 18th.

Regards,

Nancy

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: HOPPER, SARA ELIZABETH [mailto:Sara.E.Hopper@dupont.com]

Sent: Monday, July 24, 2017 2:04 PM
To: Beck, Nancy <Beck.Nancy@epa.gov>

Cc: Marshall, Venus < Marshall. Venus@epa.gov>

Subject: meeting to discuss ESA/FIFRA

Hi Nancy, I wanted to see if there was a time in August when you and I could discuss the ESA/FIFRA issue. I have some travel early in the month, but around from the 9th through Sept.

1. Happy to look at September too if that works better on your end.

Thanks!
Sara
Sara Hopper
Manager, Federal Government Affairs
DuPont Government Affairs
601 Pennsylvania Avenue NW
Suite 325, North Building
Washington, DC 20004
Ex. 6 - Personal Privacy
sara.e.hopper@dupont.com

This communication is for use by the intended recipient and contains information that may be Privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail,in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e-mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for transfers of data to third parties.

Francais Deutsch Italiano Espanol Portugues Japanese Chinese Korean

http://www.DuPont.com/corp/email_disclaimer.html

To: Goldstein, Bernard D[bdgold@pitt.edu]

From: Beck, Nancy

Sent: Mon 5/22/2017 10:48:35 PM Subject: RE: Follow-up on SRA Session

Got it. When you have a final abstract send it my way and I'll take a look.

It is a bit awkward.. I think I can be on a panel with them, but do not want to be collaborating with them, or even seen as collaborating with them.

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Monday, May 22, 2017 3:52 PM To: Beck, Nancy <Beck.Nancy@epa.gov> Subject: RE: Follow-up on SRA Session

Sorry to be unclear. I do need names for the submission, but do not need your participation in the preparation of the abstract. I apologize, as I should have realized that this might be a problem for you

Needless to say, you could withdraw at any time.

Bernie

From: Beck, Nancy [mailto:Beck.Nancy@epa.gov]

Sent: Monday, May 22, 2017 7:42 AM

To: Goldstein, Bernard D < <u>bdgold@pitt.edu</u>> **Subject:** RE: Follow-up on SRA Session

Bernie,

As I am recused from interactions with ACC, it's a bit awkward for me to be planning a session with them

As you said you don't need names just yet for the submission, why don't you just move ahead without me and lets circle back in the fall to see if it makes sense for me to join the panel.

Regards,

Nancy

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Monday, May 22, 2017 5:24 AM

To: White, Kimberly < Kimberly White@americanchemistry.com >

Cc: Rick Becker@americanchemistry.com; Joe Arvai <ilarvai@umich.edu>; Beck, Nancy

<Beck.Nancy@epa.gov>

Subject: RE: Follow-up on SRA Session

Hi Kimberly

Your changes are OK with me, but I have added a few words ("and decreasing the likelihood of the involvement of knowledgeable academic scientists in EPA review processes") to reflect the substantial concern of the academic community about the following provision in the SAB Act. (I also think that the provision is short-sighted from an industry perspective).

"(H) a Board member shall have no current grants or contracts from the Environmental Protection Agency

and shall not apply for a grant or contract for 3 years following the end of that member's service on the Board."

There is also other language in the Act which could be interpreted as the above provision being applicable to not only full SAB Board membership, but to the members of any EPA review process of any hazard or risk assessment

Let me know if the new language is acceptable to you. I'm also copying Joe Arvai and Nancy Beck in case they want to respond, either in writing or by phone, particularly as there is now no description of Administrator Pruitt's goals or activities in this area. While not necessary, we do have room in the abstract for additional language

Bernie

Bernard D. Goldstein, MD

Professor Emeritus and Dean Emeritus

University of Pittsburgh Graduate School of Public Health
130 Desoto St; Rm A-710
Pittsburgh PA 15261
Ex. 6 - Personal Privacy
From: White, Kimberly [mailto:Kimberly_White@americanchemistry.com] Sent: Friday, May 19, 2017 6:22 PM To: Goldstein, Bernard D < bdgold@pitt.edu > Cc: Becker, Rick < Rick_Becker@americanchemistry.com > Subject: RE: Follow-up on SRA Session
Dear Bernie:
Thanks for the additional information about the session and the abstract. We offer some suggestions to the abstract attached. The suggestions attempt to focus the abstract on the discussion regarding what are appropriate approaches for optimal provision of scientific advice to regulatory agencies and work to adjust some of the language that may be perceived as inflammatory.
Kind Regards,
Kimberly
Kimberly Wise White, Ph.D. American Chemistry Council

Senior Director, Chemical Products & Technology Division

Kimberly White@americanchemistry.com

700 2nd Street NE | Washington, DC | 20002

Ex. 6 - Personal Privacy

www.americanchemistry.com

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Friday, May 19, 2017 2:53 PM

To: White, Kimberly **Cc:** Becker, Rick

Subject: RE: Follow-up on SRA Session

Dear Dr White

Great news!!

My previous email to you is below; along with the original attachment of the preliminary draft

Bernie

Bernard D. Goldstein, MD

Emeritus Professor and Emeritus Dean

Graduate School of Public Health

University of Pittsburgh

Rm A710 Crabtree Hall

130 De Soto St

Pittsburgh, PA 15261

Ex. 6 - Personal Privacy

Dear Dr White

I am following up with you at the suggestion of Nancy Beck (email below) to request your involvement in a proposal for a Roundtable to be submitted to the Society for Risk Analysis for its annual meeting in Crystal City next December 10-13.

I've attached a short overview of Roundtables from the SRA web site along with a rough draft of the abstract. I am trying to focus the Roundtable on the parameters governing an effective science advisory process for a regulatory agency, rather than on the current controversy – although this is unlikely to be fully possible.

NOTE: no abstract would be needed from you, just an agreement to participate, give perhaps a 10 minute presentation and participate in the discussion during the 90 minute session. But your input on the proposal would be welcome.

One difference from the note below to Nancy is that I have been told that the proposal is more likely to be acceptable if it has a broader range of participants so it will probably 4-5 speakers rather than 3-4

I had previously reached out to Richard Becker asking for whom to approach at ACC now that Nancy had left. His response was that ACC would be interested in participating but only if EPA did as well, which I fully understand. I know he is out of town today. As you no doubt know, ACC is on record supporting the EPA SAB Act that passed the House.

There are some time constraints in getting this completed, particularly as I will be at Dow Chemical for much of next week, so hope both that you can do this and that you can respond by midweek

Many thanks for your consideration

Bernie

Bernard D. Goldstein, MD

Emeritus Professor and Emeritus Dean

Graduate School of Public Health

University of Pittsburgh

Rm A710 Crabtree Hall

130 De Soto St

Pittsburgh, PA 15261

Ex. 6 - Personal Privacy

From: Goldstein, Bernard D

Sent: Thursday, May 18, 2017 2:28 PM **To:** Beck, Nancy < Beck. Nancy @epa.gov >

Subject: Re: SRA panel

Happy to reframe. I originally had a quote from the congressman who sponsored it but this

seemed too inflammatory for SRA. Will look at this again tonight and will contact Kimberly White

Sent from my iPhone

On May 18, 2017, at 12:08 PM, Beck, Nancy < Beck. Nancy@epa.gov > wrote:

Bernie,

I think the framing of the abstract is a bit biased and needs some work.

I cant and wont speak for ACC at all, but for this topic, I direct you to Kimberly White. She has testified in front of congress on these issues. <u>Kimberly_White@americanchemistry.com</u>.

If I have more time this week I will noodle the abstract but it's a bit of a busy time here.

Regards, Nancy

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Wednesday, May 17, 2017 12:41 PM **To:** Beck, Nancy < <u>Beck.Nancy@epa.gov</u>>

Subject: RE: SRA panel

Hi Nancy
Great to hear!!
Attached is what I've written so far, and some of the directions from the SRA web site. I'm about to run out for most of the rest of the afternoon. I'd like to get this out of the way as soon as reasonably possible as am at meetings at Dow most of next week.
No abstract would be needed from you so there is nothing written with your name on it that would have to go through the EPA process, at least as I understood it many, many years ago. (As the proposer, I would be the only one with my name on the proposed abstract, but would welcome your input and that of the other panelists on the proposal).
I'm envisioning the 3 or 4 panelists for the Roundtable would have about 15 min each for presentation and the rest of the 90 minutes would be for a facilitated discussion led by the moderator
I'm thinking of asking Granger Morgan or Terry Yosie to be the moderator, but your suggestion for moderator or for another panelist who supports the ACC position on the SAB Act would be very much appreciated.
Best regards
Bernie
Bernard D. Goldstein, MD
Emeritus Professor and Emeritus Dean
Graduate School of Public Health

University of Pittsburgh

Rm A710 Crabtree Hall

130 De Soto St

Pittsburgh, PA 15261

Ex. 6 - Personal Privacy

From: Beck, Nancy [mailto:Beck.Nancy@epa.gov]

Sent: Wednesday, May 17, 2017 12:22 PM To: Goldstein, Bernard D < bdgold@pitt.edu>

Subject: SRA panel

Hi Bernie,

Got your message and am happy to consider the request. Can you send me all the information on the proposal (abstract, goals, participants, etc)?

I will have to find out if I have to run this through a clearance process—not sure how that works yet and if those procedures apply to me.

Thanks, Nancy

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator

Office of Chemical Safety and Pollution Prevention

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: White, Kimberly [mailto:Kimberly_White@americanchemistry.com]

Sent: Friday, May 19, 2017 2:35 PM

To: Goldstein, Bernard D < bdgold@pitt.edu>

Cc: Becker, Rick < Rick Becker@americanchemistry.com>

Subject: Follow-up on SRA Session

Dear Dr. Goldstein:

Thank you for your voicemail earlier today. I have had an opportunity to follow-up with Rick (cc'd on this email) and I understand you have a commitment from EPA to participate. Given the confirmation of EPA's participation, we will also confirm ACC's participation. Could you send me the proposed abstract or session description? Also it would be helpful to know of any additional information you need from ACC for the session and any deadlines.

Kind Regards,

Kimberly Wise White, Ph.D. | American Chemistry Council

Senior Director, Chemical Products & Technology Division

Kimberly White@americanchemistry.com

Ex. 6 - Personal Privacy

www.americanchemistry.com

To: Goldstein, Bernard D[bdgold@pitt.edu]

From: Beck, Nancy

Sent: Mon 5/22/2017 11:42:20 AM
Subject: RE: Follow-up on SRA Session

Bernie,

As I am recused from interactions with ACC, it's a bit awkward for me to be planning a session with them.

As you said you don't need names just yet for the submission, why don't you just move ahead without me and lets circle back in the fall to see if it makes sense for me to join the panel.

Regards,

Nancy

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Monday, May 22, 2017 5:24 AM

To: White, Kimberly < Kimberly White@americanchemistry.com >

Cc: Rick Becker@americanchemistry.com; Joe Arvai <jlarvai@umich.edu>; Beck, Nancy

<Beck.Nancy@epa.gov>

Subject: RE: Follow-up on SRA Session

Hi Kimberly

Your changes are OK with me, but I have added a few words ("and decreasing the likelihood of the involvement of knowledgeable academic scientists in EPA review processes") to reflect the substantial concern of the academic community about the following provision in the SAB Act. (I also think that the provision is short-sighted from an industry perspective).

"(H) a Board member shall have no current grants or contracts from the Environmental Protection Agency

and shall not apply for a grant or contract for 3 years following the end of that member's service on the Board."

There is also other language in the Act which could be interpreted as the above provision being applicable to not only full SAB Board membership, but to the members of any EPA review process of any hazard or risk assessment

Let me know if the new language is acceptable to you. I'm also copying Joe Arvai and Nancy Beck in case they want to respond, either in writing or by phone, particularly as there is now no description of Administrator Pruitt's goals or activities in this area. While not necessary, we do have room in the abstract for additional language

Bernie

Bernard D. Goldstein, MD

Professor Emeritus and Dean Emeritus

University of Pittsburgh Graduate School of Public Health

Pittsburgh PA 15261 Ex. 6 - Personal Privacy From: White, Kimberly [mailto:Kimberly White@americanchemistry.com] **Sent:** Friday, May 19, 2017 6:22 PM To: Goldstein, Bernard D < bdgold@pitt.edu> Cc: Becker, Rick < Rick Becker@americanchemistry.com> Subject: RE: Follow-up on SRA Session Dear Bernie: Thanks for the additional information about the session and the abstract. We offer some suggestions to the abstract attached. The suggestions attempt to focus the abstract on the discussion regarding what are appropriate approaches for optimal provision of scientific advice to regulatory agencies and work to adjust some of the language that may be perceived as inflammatory. Kind Regards, Kimberly Kimberly Wise White, Ph.D. | American Chemistry Council Senior Director, Chemical Products & Technology Division Kimberly White@americanchemistry.com

130 Desoto St; Rm A-710

700 2nd Street NE | Washington, DC | 20002

Ex. 6 - Personal Privacy

www.americanchemistry.com

Ex. 6 - Personal Privacy

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu] Sent: Friday, May 19, 2017 2:53 PM To: White, Kimberly Cc: Becker, Rick Subject: RE: Follow-up on SRA Session
Dear Dr White
Great news!!
My previous email to you is below; along with the original attachment of the preliminary draft Bernie
Bernard D. Goldstein, MD
Emeritus Professor and Emeritus Dean
Graduate School of Public Health
University of Pittsburgh
Rm A710 Crabtree Hall
130 De Soto St
Pittsburgh, PA 15261

Dear Dr White

I am following up with you at the suggestion of Nancy Beck (email below) to request your involvement in a proposal for a Roundtable to be submitted to the Society for Risk Analysis for its annual meeting in Crystal City next December 10-13.

I've attached a short overview of Roundtables from the SRA web site along with a rough draft of the abstract. I am trying to focus the Roundtable on the parameters governing an effective science advisory process for a regulatory agency, rather than on the current controversy – although this is unlikely to be fully possible.

NOTE: no abstract would be needed from you, just an agreement to participate, give perhaps a 10 minute presentation and participate in the discussion during the 90 minute session. But your input on the proposal would be welcome.

One difference from the note below to Nancy is that I have been told that the proposal is more likely to be acceptable if it has a broader range of participants so it will probably 4-5 speakers rather than 3-4.

I had previously reached out to Richard Becker asking for whom to approach at ACC now that Nancy had left. His response was that ACC would be interested in participating but only if EPA did as well, which I fully understand. I know he is out of town today. As you no doubt know, ACC is on record supporting the EPA SAB Act that passed the House.

There are some time constraints in getting this completed, particularly as I will be at Dow Chemical for much of next week, so hope both that you can do this and that you can respond by midweek

Many thanks for your consideration

Bernie

Bernard D. Goldstein, MD

Emeritus Professor and Emeritus Dean

Graduate School of Public Health

University of Pittsburgh

Rm A710 Crabtree Hall

130 De Soto St

Pittsburgh, PA 15261

Ex. 6 - Personal Privacy

From: Goldstein, Bernard D

Sent: Thursday, May 18, 2017 2:28 PM **To:** Beck, Nancy < Beck. Nancy @epa.gov >

Subject: Re: SRA panel

Happy to reframe. I originally had a quote from the congressman who sponsored it but this seemed too inflammatory for SRA. Will look at this again tonight and will contact Kimberly White

Sent from my iPhone

On May 18, 2017, at 12:08 PM, Beck, Nancy < Beck. Nancy@epa.gov > wrote:

Bernie,

I think the framing of the abstract is a bit biased and needs some work.

I cant and wont speak for ACC at all, but for this topic, I direct you to Kimberly White. She has testified in front of congress on these issues. <u>Kimberly White@americanchemistry.com</u>.

If I have more time this week I will noodle the abstract but it's a bit of a busy time here.

Regards, Nancy

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: Goldstein, Bernard D [mailto:bdgold@pitt.edu]

Sent: Wednesday, May 17, 2017 12:41 PM **To:** Beck, Nancy <<u>Beck.Nancy@epa.gov</u>>

Subject: RE: SRA panel

Hi Nancy

Great to hear!!
Attached is what I've written so far, and some of the directions from the SRA web site. I'm about to run out for most of the rest of the afternoon. I'd like to get this out of the way as soon as reasonably possible as am at meetings at Dow most of next week.
No abstract would be needed from you so there is nothing written with your name on it that would have to go through the EPA process, at least as I understood it many, many years ago. (As the proposer, I would be the only one with my name on the proposed abstract, but would welcome your input and that of the other panelists on the proposal).
I'm envisioning the 3 or 4 panelists for the Roundtable would have about 15 min each for presentation and the rest of the 90 minutes would be for a facilitated discussion led by the moderator
I'm thinking of asking Granger Morgan or Terry Yosie to be the moderator, but your suggestion for moderator or for another panelist who supports the ACC position on the SAB Act would be very much appreciated.
Best regards
Bernie
Bernard D. Goldstein, MD
Emeritus Professor and Emeritus Dean
Graduate School of Public Health
University of Pittsburgh
Rm A710 Crabtree Hall

130 De Soto St

Pittsburgh, PA 15261

Ex. 6 - Personal Privacy

From: Beck, Nancy [mailto:Beck.Nancy@epa.gov]

Sent: Wednesday, May 17, 2017 12:22 PM To: Goldstein, Bernard D < bdgold@pitt.edu>

Subject: SRA panel

Hi Bernie,

Got your message and am happy to consider the request. Can you send me all the information on the proposal (abstract, goals, participants, etc)?

I will have to find out if I have to run this through a clearance process—not sure how that works yet and if those procedures apply to me.

Thanks, Nancy

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator

Office of Chemical Safety and Pollution Prevention

Ex. 6 - Personal Privacy

beck.i	nancy(a	epa.gov

From: White, Kimberly [mailto:Kimberly White@americanchemistry.com]

Sent: Friday, May 19, 2017 2:35 PM

To: Goldstein, Bernard D < bdgold@pitt.edu >

Cc: Becker, Rick < Rick Becker@americanchemistry.com>

Subject: Follow-up on SRA Session

Dear Dr. Goldstein:

Thank you for your voicemail earlier today. I have had an opportunity to follow-up with Rick (cc'd on this email) and I understand you have a commitment from EPA to participate. Given the confirmation of EPA's participation, we will also confirm ACC's participation. Could you send me the proposed abstract or session description? Also it would be helpful to know of any additional information you need from ACC for the session and any deadlines.

Kind Regards,

Kimberly Wise White, Ph.D. | American Chemistry Council

Senior Director, Chemical Products & Technology Division

Kimberly White@americanchemistry.com

700 2nd Street NE | Washington, DC | 20002

Ex. 6 - Personal Privacy

To: Cc: From: Sent:	James McVaney[james.mcvaney@bayer.com] Ethan Mathews[mathews@dc.ncga.com] Beck, Nancy Wed 7/19/2017 7:54:48 PM
Subject:	RE: Row crop farm tour - Corn
Thanks J	im! I look forward to meeting Ethan tomorrow.
Nancy	
Nancy B	. Beck, Ph.D., DABT
Deputy A	Assistant Administrator, OCSPP
Ex. 6 - Pe	ersonal Privacy
heck nan	cy@epa.gov
DCCK.Han	<u>cy (w cpa.gov</u>
	ames McVaney [mailto:james.mcvaney@bayer.com] ednesday, July 19, 2017 1:34 PM
To: Becl	k, Nancy <beck.nancy@epa.gov></beck.nancy@epa.gov>
	n Mathews <mathews@dc.ncga.com> Row crop farm tour - Corn</mathews@dc.ncga.com>
Subject	Towerop laim tour Com
Mathews	hen we first spoke you mentioned that you would like to tour a row crop farm. I have cc'd Ethan of the National Corn Growers Association. You will be with him tomorrow at the Pesticide Policy
	meeting, which he co-chairs. NCGA would be able to organize a tour for you and other Agency would be informative and show the use of FIFRA regulated products in that setting.
l'Il leave i	t to Ethan to follow up but wanted to "set the table."

Best,

:	
 1	m

Jim McVaney

Senior Director, Federal Affairs & Policy

Bayer: Science For A Better Life

Bayer Corporation

Bayer Corp-CGR-USGR

801 Pennsylvania Avenue, NW

Suite 745

Washington, DC 20004 US

Ex. 6 - Personal Privacy

E-mail: james.mcvaney@bayer.com

Web: http://www.bayer.com

~

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not



To: James McVaney[james.mcvaney@bayer.com] Cc: Marshall, Venus[Marshall.Venus@epa.gov] From: Beck, Nancy Sent: Fri 6/23/2017 9:54:12 PM Subject: RE: ACC Alum and Meeting follow up Hi Jim, Nice to "meet" you. My calendar is pretty crazy packed next week. Why don't we try for a 30 minute window after the July 4th holiday. Venus, can you help us find a window? Regards, Nancy Nancy B. Beck, Ph.D., DABT Deputy Assistant Administrator, OCSPP Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: James McVaney [mailto:james.mcvaney@bayer.com]

Sent: Friday, June 23, 2017 2:03 PM

To: Beck, Nancy <Beck.Nancy@epa.gov> **Subject:** ACC Alum and Meeting follow up

Nancy,

issues. I have sent an LinkedIn request to connect, noting that I am also an ACC Alum, having run the energy and climate team in the early 2000s. I currently run all of Bayer's advocacy for our CropScience business. I am hoping we can get coffee next week to talk shop and follow up on the meeting you had with the group from CropLife last week. We were not able to be present but have a number of things cooking right now. Please let me know if you have availability. Best, Jim Jim McVaney Senior Director, Federal Affairs & Policy Bayer: Science For A Better Life **Bayer Corporation** Bayer Corp-CGR-USGR 801 Pennsylvania Avenue, NW Suite 745 Washington, DC 20004 US Ex. 6 - Personal Privacy

This is to follow up on a meeting you had last week with a group from CropLife, and to connect on specific

E-mail: james.mcvaney@bayer.com

Web: http://www.bayer.com

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.

To: Schmit, Ryan[schmit.ryan@epa.gov]; Jakob, Avivah[Jakob.Avivah@epa.gov]

From: Beck, Nancy

Sent: Tue 7/25/2017 1:21:46 PM

Subject: Fwd: Chemical Makers Urge EPA to Accept Non-Animal Safety Data

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

Beck.Nancy@epa.gov

Begin forwarded message:

From: "Deziel, Dennis (DR)" < <u>DRDeziel@dow.com</u>>

Date: July 18, 2017 at 1:18:18 PM EDT

To: "Beck, Nancy" < Beck.Nancy@epa.gov>

Subject: Chemical Makers Urge EPA to Accept Non-Animal Safety Data

Nancy,

Dow is a leader in non-animal testing methods, including extensive, collaborative work with EPA's National Center for Computational Toxicology. We want to engage on this issue in as helpful way as possible. One of our leaders on this issue, Mike Witt, head of our toxicology center, will be in town August 1st. Would you be available to meet when he is here to discuss this issue? Or we could meet with others as you recommend.

Thank you, Dennis

Dennis Deziel Government Affairs

The Dow Chemical Company

500 North Capitol Street, NW Suite 200

Washington DC 20001

Ex. 6 - Personal Privacy

E-Mail: DRDeziel@dow.com



--

Bloomberg News

Chemical Makers Urge EPA to Accept Non-Animal Safety Data

By <u>Pat Rizzuto</u>

Chemical manufacturers want the EPA to be more receptive than they say the European Chemicals Agency has been in accepting chemical safety data derived from non-animal tests.

"We've had challenges in the EU getting many of these alternatives accepted. We hope the U.S. will be a more friendly place," Athena Keene, a senior toxicologist at Afton Chemical Corp., said at a recent science policy meeting.

Afton, a subsidiary of the NewMarket Corp., which makes fuel and lubricant additives, has registered chemicals under the EU's registration, evaluation, authorization and restriction of chemicals, or REACH, law. REACH encourages the use of non-animal tests, yet animal welfare groups and chemical manufacturers have appealed many decisions in which the European Chemicals Agency rejected non-animal data the companies sought to submit.

The Environmental Protection Agency soon will invite chemical manufacturers, trade associations, animal welfare advocates, and academic and other scientists to help shape an agency strategy to develop and use the results from non-animal, or "alternative," tests for chemical decision making, said Tala Henry, who directs the risk assessment division of the EPA's Office of Pollution Prevention and Toxics. Keene and Henry were among the speakers at a July 12 Toxicology Forum meeting that discussed the Lautenberg Chemical Safety Act, which amended the Toxic Substances Control Act in 2016.

TSCA's amendments require the EPA to develop a non-animal testing strategy by June 22, 2018, to promote the development and use of new scientifically valid test methods that don't use mammals or other vertebrates. That strategy is part a broader requirement for EPA to reduce and replace the use of animals at a time when more tests may be required.

The EPA is deciding whether to seek public participation through a workshop, releasing a draft concept document, or some other method, Henry said. The agency expects to invite interested parties to provide input in a few months, she said.

Reducing Liability

Harvey Clewell, a senior scientist at ScitoVation, a research institute specializing in cell-based and computational methods as chemical evaluation methods, echoed Keene's point

that some European chemical regulators have not used available non-animal test methods.

The U.S., however, has a growing academic, federal and industry scientific infrastructure supporting their development and use, he said. Clewell pointed to federal agencies such the EPA and National Institute of Environmental Health Sciences (NIEHS), which have been developing and using a spectrum of automated chemical testing systems.

Using alternative tests "just makes good sense," especially in the early stages of a new chemical's development, Clewell said. "There's a lot of liability potential for chemicals. They can cost a company a lot of money once they are out there. Wouldn't it behoove a company to run some quick tests and say 'this has red flags why should we pursue it'."

Suzanne Hartigan, director of science policy and regulatory affairs at the International Fragrance Association North America, said fragrance makers already have developed strategies to obtain chemical safety data from alternative tests, so they could comply with the EU's Cosmetics Products Regulation and its predecessor—the Cosmetics Directive—which phased out the use of animal tests on cosmetics and their ingredients.

The Research Institute for Fragrance Materials, Inc., which assesses fragrance safety, has developed a phased in, or "tiered," testing strategy that begins with evaluating existing data for a particular fragrance, proceeds to examining information about similar compounds, and builds toward in vitro and computer-modeled tests, Hartigan said. After such alternative data sources have been utilized, animal tests can be considered, she said, urging EPA to consider some of these strategies.

No Double Standard

Henry said EPA already would review non-animal chemical safety data if companies submitted it but added, "It's not flooding into us."

The more companies submit alternative data, the more it will help the agency understand their uses and limitations, she said.

Richard Denison, lead senior scientist with the Environmental Defense Fund, said that group supports the use of alternative tests. Details about tests used to generate data submitted to the EPA should, however, be made available to build public confidence in the tests' predictions, he said. Protocols used for statutorily required animal tests are publicly available.

Many of the assays the EPA uses for its automated chemical testing program, called ToxCast, and that the NIEHS uses for a similar program called Tox21, are proprietary, Denison said.

Alternative test advocates also should avoid a double standard, Denison said.

There's a tendency for proponents to want to use data from an alternative test if it suggests a chemical would not raise health or environmental concerns, he said. Yet if such tests show a problem, then the proponents argue the tests aren't valid because they don't reflect the "real world," Denison said.

To: Marshall, Venus[Marshall.Venus@epa.gov]

From: Beck, Nancy

Sent: Fri 6/23/2017 8:37:03 PM

Subject: FW: meeting re: TSCA Section 5

I'm fine with adding Jeff.

Thanks!

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: HOPPER, SARA ELIZABETH [mailto:Sara.E.Hopper@dupont.com]

Sent: Friday, June 23, 2017 4:22 PM

To: Beck, Nancy <Beck.Nancy@epa.gov>

Cc: Marshall, Venus <Marshall.Venus@epa.gov>; DEKLEVA, LYNN ANN <Lynn-

Ann.Dekleva-1@dupont.com>

Subject: RE: meeting re: TSCA Section 5

Thanks very much Nancy and Venus! We have a time on your calendar on July 10th. Venus, I forwarded the invite to my colleague Lynn Dekleva, copied above, so you should get a response from her too. Nancy, Lynn and I thought it might make sense for Jeff Morris to join us, if you agree. Re: specific topics, Lynn should probably weigh in, but at a high level, the need for transparency and more open communication is one area of concern for us, and a tendency towards overly precautionary approaches and actions (vs. the risk-based approach mandated by LCSA) is another. I hope that is helpful. If more background would be helpful, I can work with Lynn to get that to you.

Thanks again to both you and Venus for responding so quickly and helping us to get this set up.

Have a great weekend!
Sara
From: Beck, Nancy [mailto:Beck.Nancy@epa.gov] Sent: Thursday, June 22, 2017 6:21 PM To: HOPPER, SARA ELIZABETH < Sara. E. Hopper@dupont.com > Cc: Marshall, Venus < Marshall.Venus@epa.gov > Subject: [EXTERNAL] RE: meeting re: TSCA Section 5
Hi Sarah,
Next week is pretty crazy but I think we can find 30 min the week of July 10. Venus, can you please help us find a window?
If there is a specific topic within the new chemicals program and you would like some of our leadership team to join me please let me know.
Regards, Nancy
Nancy B. Beck, Ph.D., DABT
Deputy Assistant Administrator, OCSPP
Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: HOPPER, SARA ELIZABETH [mailto:Sara.E.Hopper@dupont.com] Sent: Thursday, June 22, 2017 4:45 PM To: Beck, Nancy < Beck. Nancy@epa.gov> Subject: meeting re: TSCA Section 5 Hi Nancy. Just left you a voice mail. Would you have time to meet with my colleague, Lynn Dekleva, and me to discuss our recent experiences with the new chemicals program? Lynn will be in town next week and we would have some time Wed. afternoon the 28th. If that doesn't work on your end, could we look at the week of July 10th, or the following week if needed? Thank you very much! Sara Sara Hopper Manager, Federal Government Affairs **DuPont Government Affairs** 601 Pennsylvania Avenue NW

Ex. 6 - Personal Privacy

Suite 325, North Building

Washington, DC 20004

sara.e.hopper@dupont.com

This communication is for use by the intended recipient and contains information that may be Privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail, in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e-mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for transfers of data to third parties.

Francais Deutsch Italiano Espanol Portugues Japanese Chinese Korean

http://www.DuPont.com/corp/email_disclaimer.html

This communication is for use by the intended recipient and contains information that may be Privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail, in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e-mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for transfers of data to third parties.

Francais Deutsch Italiano Espanol Portugues Japanese Chinese Korean

http://www.DuPont.com/corp/email_disclaimer.html

To: Cleland-Hamnett, Wendy[Cleland-Hamnett.Wendy@epa.gov]

From: Beck, Nancy

Sent: Tue 7/25/2017 11:23:24 AM

Subject: Fwd: Chemical Makers Urge EPA to Accept Non-Animal Safety Data

FYI. Dow wants to talk about alternative testing.

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

Beck.Nancy@epa.gov

Begin forwarded message:

From: "Deziel, Dennis (DR)" < <u>DRDeziel@dow.com</u>>

Date: July 18, 2017 at 1:18:18 PM EDT **To:** "Beck, Nancy" < <u>Beck.Nancy@epa.gov</u>>

Subject: Chemical Makers Urge EPA to Accept Non-Animal Safety Data

Nancy,

Dow is a leader in non-animal testing methods, including extensive, collaborative work with EPA's National Center for Computational Toxicology. We want to engage on this issue in as helpful way as possible. One of our leaders on this issue, Mike Witt, head of our toxicology center, will be in town August 1st. Would you be available to meet when he is here to discuss this issue? Or we could meet with others as you recommend.

Thank you, Dennis

Dennis Deziel Government Affairs

The Dow Chemical Company

500 North Capitol Street, NW Suite 200

Washington DC 20001

Ex. 6 - Personal Privacy



__

Bloomberg News

Chemical Makers Urge EPA to Accept Non-Animal Safety Data

By Pat Rizzuto

Chemical manufacturers want the EPA to be more receptive than they say the European Chemicals Agency has been in accepting chemical safety data derived from non-animal tests.

"We've had challenges in the EU getting many of these alternatives accepted. We hope the U.S. will be a more friendly place," Athena Keene, a senior toxicologist at Afton Chemical Corp., said at a recent science policy meeting.

Afton, a subsidiary of the NewMarket Corp., which makes fuel and lubricant additives, has registered chemicals under the EU's registration, evaluation, authorization and restriction of chemicals, or REACH, law. REACH encourages the use of non-animal tests, yet animal welfare groups and chemical manufacturers have appealed many decisions in which the European Chemicals Agency rejected non-animal data the companies sought to submit.

The Environmental Protection Agency soon will invite chemical manufacturers, trade associations, animal welfare advocates, and academic and other scientists to help shape an agency strategy to develop and use the results from non-animal, or "alternative," tests for chemical decision making, said Tala Henry, who directs the risk assessment division of the EPA's Office of Pollution Prevention and Toxics. Keene and Henry were among the speakers at a July 12 Toxicology Forum meeting that discussed the Lautenberg Chemical Safety Act, which amended the Toxic Substances Control Act in 2016.

TSCA's amendments require the EPA to develop a non-animal testing strategy by June 22, 2018, to promote the development and use of new scientifically valid test methods that don't use mammals or other vertebrates. That strategy is part a broader requirement for EPA to reduce and replace the use of animals at a time when more tests may be required.

The EPA is deciding whether to seek public participation through a workshop, releasing a draft concept document, or some other method, Henry said. The agency expects to invite interested parties to provide input in a few months, she said.

Reducing Liability

Harvey Clewell, a senior scientist at ScitoVation, a research institute specializing in cell-

based and computational methods as chemical evaluation methods, echoed Keene's point that some European chemical regulators have not used available non-animal test methods.

The U.S., however, has a growing academic, federal and industry scientific infrastructure supporting their development and use, he said. Clewell pointed to federal agencies such the EPA and National Institute of Environmental Health Sciences (NIEHS), which have been developing and using a spectrum of automated chemical testing systems.

Using alternative tests "just makes good sense," especially in the early stages of a new chemical's development, Clewell said. "There's a lot of liability potential for chemicals. They can cost a company a lot of money once they are out there. Wouldn't it behoove a company to run some quick tests and say 'this has red flags why should we pursue it'."

Suzanne Hartigan, director of science policy and regulatory affairs at the International Fragrance Association North America, said fragrance makers already have developed strategies to obtain chemical safety data from alternative tests, so they could comply with the EU's Cosmetics Products Regulation and its predecessor—the Cosmetics Directive—which phased out the use of animal tests on cosmetics and their ingredients.

The Research Institute for Fragrance Materials, Inc., which assesses fragrance safety, has developed a phased in, or "tiered," testing strategy that begins with evaluating existing data for a particular fragrance, proceeds to examining information about similar compounds, and builds toward in vitro and computer-modeled tests, Hartigan said. After such alternative data sources have been utilized, animal tests can be considered, she said, urging EPA to consider some of these strategies.

No Double Standard

Henry said EPA already would review non-animal chemical safety data if companies submitted it but added, "It's not flooding into us."

The more companies submit alternative data, the more it will help the agency understand their uses and limitations, she said.

Richard Denison, lead senior scientist with the Environmental Defense Fund, said that group supports the use of alternative tests. Details about tests used to generate data submitted to the EPA should, however, be made available to build public confidence in the tests' predictions, he said. Protocols used for statutorily required animal tests are publicly available.

Many of the assays the EPA uses for its automated chemical testing program, called ToxCast, and that the NIEHS uses for a similar program called Tox21, are proprietary, Denison said.

Alternative test advocates also should avoid a double standard, Denison said.

There's a tendency for proponents to want to use data from an alternative test if it suggests a chemical would not raise health or environmental concerns, he said. Yet if such tests show a problem, then the proponents argue the tests aren't valid because they don't reflect the "real world," Denison said.



To: Milhouse, Gloria[Milhouse.Gloria@epa.gov]

From: Beck, Nancy

Sent: Wed 7/19/2017 2:04:47 PM

Subject: Fwd: Chemical Makers Urge EPA to Accept Non-Animal Safety Data

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

Beck.Nancy@epa.gov

Begin forwarded message:

From: "Deziel, Dennis (DR)" < DRDeziel@dow.com>

Date: July 19, 2017 at 10:01:48 AM EDT

To: "Beck, Nancy" < Beck. Nancy@epa.gov >, "Marshall, Venus"

< Marshall. Venus@epa.gov>

Cc: "Witt, Mike (M)" < MEWitt@dow.com>

Subject: RE: Chemical Makers Urge EPA to Accept Non-Animal Safety Data

Venus,

We can be available on August 1 at either 11am or anytime 3:30pm or later. 30 minutes would be great. Thank you!

From: Beck, Nancy [mailto:Beck.Nancy@epa.gov]

Sent: Tuesday, July 18, 2017 5:44 PM

To: Deziel, Dennis (DR) < <u>DRDeziel@dow.com</u>> **Cc:** Marshall, Venus < <u>Marshall.Venus@epa.gov</u>>

Subject: RE: Chemical Makers Urge EPA to Accept Non-Animal Safety Data

Dennis-

I'm happy to meet with Mike Witt and can invite our leads for the development of our alternatives strategy.

Please work with Venus to find a 30 minute window that will work.
Nancy
Nancy B. Beck, Ph.D., DABT
Deputy Assistant Administrator, OCSPP
Ex. 6 - Personal Privacy
beck.nancy@epa.gov
From: Deziel, Dennis (DR) [mailto:DRDeziel@dow.com] Sent: Tuesday, July 18, 2017 1:18 PM To: Beck, Nancy < Beck.Nancy@epa.gov > Subject: Chemical Makers Urge EPA to Accept Non-Animal Safety Data
Nancy,
Dow is a leader in non-animal testing methods, including extensive, collaborative work with EPA's National Center for Computational Toxicology. We want to engage on this issue in as helpful way as possible. One of our leaders on this issue, Mike Witt, head of our toxicology center, will be in town August 1 st . Would you be available to meet when he is here to discuss this issue? Or we could meet with others as you recommend.
Thank you, Dennis
Dennis Deziel Government Affairs

The Dow Chemical Company

500 North Capitol Street, NW Suite 200

Washington DC 20001

Ex. 6 - Personal Privacy

E-Mail: DRDeziel@dow.com



--

Bloomberg News

Chemical Makers Urge EPA to Accept Non-Animal Safety Data

By Pat Rizzuto

Chemical manufacturers want the EPA to be more receptive than they say the European Chemicals Agency has been in accepting chemical safety data derived from non-animal tests.

"We've had challenges in the EU getting many of these alternatives accepted. We hope the U.S. will be a more friendly place," Athena Keene, a senior toxicologist at Afton Chemical Corp., said at a recent science policy meeting.

Afton, a subsidiary of the NewMarket Corp., which makes fuel and lubricant additives, has registered chemicals under the EU's registration, evaluation, authorization and restriction of chemicals, or REACH, law. REACH encourages the use of non-animal tests, yet animal welfare groups and chemical manufacturers have appealed many decisions in which the European Chemicals Agency rejected non-animal data the companies sought to submit.

The Environmental Protection Agency soon will invite chemical manufacturers, trade associations, animal welfare advocates, and academic and other scientists to help shape an agency strategy to develop and use the results from non-animal, or "alternative," tests for chemical decision making, said Tala Henry, who directs the risk assessment division of the EPA's Office of Pollution Prevention and Toxics. Keene and Henry were among the speakers at a July 12 Toxicology Forum meeting that discussed the Lautenberg Chemical Safety Act, which amended the Toxic Substances Control Act in 2016.

TSCA's amendments require the EPA to develop a non-animal testing strategy by June 22, 2018, to promote the development and use of new scientifically valid test methods that don't use mammals or other vertebrates. That strategy is part a broader requirement for EPA to reduce and replace the use of animals at a time when more tests may be required.

The EPA is deciding whether to seek public participation through a workshop, releasing a draft concept document, or some other method, Henry said. The agency expects to invite interested parties to provide input in a few months, she said.

Reducing Liability

Harvey Clewell, a senior scientist at ScitoVation, a research institute specializing in cell-based and computational methods as chemical evaluation methods, echoed Keene's point that some European chemical regulators have not used available non-animal test methods.

The U.S., however, has a growing academic, federal and industry scientific infrastructure supporting their development and use, he said. Clewell pointed to federal agencies such the EPA and National Institute of Environmental Health Sciences (NIEHS), which have been developing and using a spectrum of automated chemical testing systems.

Using alternative tests "just makes good sense," especially in the early stages of a new chemical's development, Clewell said. "There's a lot of liability potential for chemicals. They can cost a company a lot of money once they are out there. Wouldn't it behoove a company to run some quick tests and say 'this has red flags why should we pursue it'."

Suzanne Hartigan, director of science policy and regulatory affairs at the International Fragrance Association North America, said fragrance makers already have developed strategies to obtain chemical safety data from alternative tests, so they could comply with the EU's Cosmetics Products Regulation and its predecessor—the Cosmetics Directive—which phased out the use of animal tests on cosmetics and their ingredients.

The Research Institute for Fragrance Materials, Inc., which assesses fragrance safety, has developed a phased in, or "tiered," testing strategy that begins with evaluating existing data for a particular fragrance, proceeds to examining information about similar compounds, and builds toward in vitro and computer-modeled tests, Hartigan said. After such alternative data sources have been utilized, animal tests can be considered, she said, urging EPA to consider some of these strategies.

No Double Standard

Henry said EPA already would review non-animal chemical safety data if companies submitted it but added, "It's not flooding into us."

The more companies submit alternative data, the more it will help the agency understand their uses and limitations, she said.

Richard Denison, lead senior scientist with the Environmental Defense Fund, said that group supports the use of alternative tests. Details about tests used to generate data submitted to the EPA should, however, be made available to build public confidence in the tests' predictions, he said. Protocols used for statutorily required animal tests are publicly available.

Many of the assays the EPA uses for its automated chemical testing program, called ToxCast, and that the NIEHS uses for a similar program called Tox21, are proprietary, Denison said.

Alternative test advocates also should avoid a double standard, Denison said.

There's a tendency for proponents to want to use data from an alternative test if it suggests a chemical would not raise health or environmental concerns, he said. Yet if such tests show a problem, then the proponents argue the tests aren't valid because they don't reflect the "real world," Denison said.

To: Deziel, Dennis (DR)[DRDeziel@dow.com]

Cc: Venus Marshall (Marshall.Venus@epa.gov)[Marshall.Venus@epa.gov]

From: Beck, Nancy

Sent: Tue 7/18/2017 9:44:10 PM

Subject: RE: Chemical Makers Urge EPA to Accept Non-Animal Safety Data

Dennis—

I'm happy to meet with Mike Witt and can invite our leads for the development of our alternatives strategy.

Please work with Venus to find a 30 minute window that will work.

Nancy

Nancy B. Beck, Ph.D., DABT

Deputy Assistant Administrator, OCSPP

Ex. 6 - Personal Privacy

beck.nancy@epa.gov

From: Deziel, Dennis (DR) [mailto:DRDeziel@dow.com]

Sent: Tuesday, July 18, 2017 1:18 PM **To:** Beck, Nancy <Beck.Nancy@epa.gov>

Subject: Chemical Makers Urge EPA to Accept Non-Animal Safety Data

Nancy,

Dow is a leader in non-animal testing methods, including extensive, collaborative work with EPA's National Center for Computational Toxicology. We want to engage on this issue in as

helpful way as possible. One of our leaders on this issue, Mike Witt, head of our toxicology center, will be in town August 1st. Would you be available to meet when he is here to discuss this issue? Or we could meet with others as you recommend.

Thank you, Dennis

Dennis Deziel Government Affairs

The Dow Chemical Company

500 North Capitol Street, NW Suite 200

Washington DC 20001

Ex. 6 - Personal Privacy

E-Mail: DRDeziel@dow.com



--

Bloomberg News

Chemical Makers Urge EPA to Accept Non-Animal Safety Data

By Pat Rizzuto

Chemical manufacturers want the EPA to be more receptive than they say the European Chemicals Agency has been in accepting chemical safety data derived from non-animal tests.

"We've had challenges in the EU getting many of these alternatives accepted. We hope the U.S. will be a more friendly place," Athena Keene, a senior toxicologist at Afton Chemical Corp., said at a recent science policy meeting.

Afton, a subsidiary of the NewMarket Corp., which makes fuel and lubricant additives, has registered chemicals under the EU's registration, evaluation, authorization and restriction of chemicals, or REACH, law. REACH encourages the use of non-animal tests, yet animal welfare groups and chemical manufacturers have appealed many decisions in which the European Chemicals Agency rejected non-animal data the companies sought to submit.

The Environmental Protection Agency soon will invite chemical manufacturers, trade associations, animal welfare advocates, and academic and other scientists to help shape an agency strategy to develop and use the results from non-animal, or "alternative," tests for

chemical decision making, said Tala Henry, who directs the risk assessment division of the EPA's Office of Pollution Prevention and Toxics. Keene and Henry were among the speakers at a July 12 Toxicology Forum meeting that discussed the Lautenberg Chemical Safety Act, which amended the Toxic Substances Control Act in 2016.

TSCA's amendments require the EPA to develop a non-animal testing strategy by June 22, 2018, to promote the development and use of new scientifically valid test methods that don't use mammals or other vertebrates. That strategy is part a broader requirement for EPA to reduce and replace the use of animals at a time when more tests may be required.

The EPA is deciding whether to seek public participation through a workshop, releasing a draft concept document, or some other method, Henry said. The agency expects to invite interested parties to provide input in a few months, she said.

Reducing Liability

Harvey Clewell, a senior scientist at ScitoVation, a research institute specializing in cell-based and computational methods as chemical evaluation methods, echoed Keene's point that some European chemical regulators have not used available non-animal test methods.

The U.S., however, has a growing academic, federal and industry scientific infrastructure supporting their development and use, he said. Clewell pointed to federal agencies such the EPA and National Institute of Environmental Health Sciences (NIEHS), which have been developing and using a spectrum of automated chemical testing systems.

Using alternative tests "just makes good sense," especially in the early stages of a new chemical's development, Clewell said. "There's a lot of liability potential for chemicals. They can cost a company a lot of money once they are out there. Wouldn't it behoove a company to run some quick tests and say 'this has red flags why should we pursue it'."

Suzanne Hartigan, director of science policy and regulatory affairs at the International Fragrance Association North America, said fragrance makers already have developed strategies to obtain chemical safety data from alternative tests, so they could comply with the EU's Cosmetics Products Regulation and its predecessor—the Cosmetics Directive—which phased out the use of animal tests on cosmetics and their ingredients.

The Research Institute for Fragrance Materials, Inc., which assesses fragrance safety, has developed a phased in, or "tiered," testing strategy that begins with evaluating existing data for a particular fragrance, proceeds to examining information about similar compounds, and builds toward in vitro and computer-modeled tests, Hartigan said. After such alternative data sources have been utilized, animal tests can be considered, she said, urging EPA to consider some of these strategies.

No Double Standard

Henry said EPA already would review non-animal chemical safety data if companies submitted it but added, "It's not flooding into us."

The more companies submit alternative data, the more it will help the agency understand their uses and limitations, she said.

Richard Denison, lead senior scientist with the Environmental Defense Fund, said that group supports the use of alternative tests. Details about tests used to generate data submitted to the EPA should, however, be made available to build public confidence in the tests' predictions, he said. Protocols used for statutorily required animal tests are publicly available.

Many of the assays the EPA uses for its automated chemical testing program, called ToxCast, and that the NIEHS uses for a similar program called Tox21, are proprietary, Denison said.

Alternative test advocates also should avoid a double standard, Denison said.

There's a tendency for proponents to want to use data from an alternative test if it suggests a chemical would not raise health or environmental concerns, he said. Yet if such tests show a problem, then the proponents argue the tests aren't valid because they don't reflect the "real world," Denison said.